NEW YORK (GenomeWeb News) – Caliper Life Sciences today reported that its second-quarter revenues fell around 6 percent, but were up 8 percent on an organic basis, as the firm trimmed its net loss. It also beat analysts' consensus estimate for both revenues and net loss.

The Hopkinton, Mass.-based firm's stock was up 11 percent to $1.95 in early Thursday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.